US WorldMeds acquires Orbus Therapeutics to advance brain-cancer drug eflornithine
What's the deal? US WorldMeds has acquired Orbus Therapeutics, a privately held pharmaceutical company developing investigational eflornithine for rare and serious brain tumors. The deal value was undisclosed, though Orbus is eligible for development, regulatory, and sales-based milestone payments plus tiered royalties on US net sales.
The transaction adds Orbus' late-stage program in recurrent Grade 3 astrocytoma, a rare malignant glioma, to US WorldMeds' rare-disease portfolio. Orbus is now a wholly owned subsidiary.
What's the endgame? US WorldMeds already commercializes eflornithine as IWILFIN for a separate rare oncology indication, giving it experience with the molecule. "We believe our development and commercialization capabilities can help advance the program toward its next chapter," said chief executive officer P. Breckinridge Jones.
Why now? The deal builds on Orbus' Phase 3 STELLAR trial, which tested eflornithine with lomustine in 343 patients. The results were published this year in the Journal of Clinical Oncology .
The trial did not improve overall survival across the full population — its primary endpoint. But a prespecified analysis of 196 patients with IDH-mutant Grade 3 astrocytoma showed median overall survival of 34.9 months versus 23.5 months for lomustine alone, and progression-free survival of 15.8 months versus 7.2 months.
What could go wrong? Eflornithine remains investigational for this use, and the findings support a narrowly defined subgroup, not a broad glioma claim. The subset also carried notable side effects, including hearing impairment in 24% of patients versus none on lomustine alone.
The signal: While larger pharma pays billions for differentiated brain-cancer assets, this smaller, undisclosed-price deal is less about scale than advancing a promising but regulatory-uncertain niche therapy for an underserved patient group.
Read more: prnewswire.com
Image credit: Generated with Gemini
